Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $808.67, a high ...

Federal jurors in Delaware found that Amgen violated antitrust laws by bundling its cholesterol treatment with substantial ...

New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced st ...

Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

Fintel reports that on May 30, 2025, Wells Fargo downgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from ...

Regeneron (REGN) performed poorly. REGN stock entered a prolonged downtrend, despite no major news that would explain the decline. Last Friday, May 30, Regeneron and its drug development partner ...

23andMe has said it wants to allow new bids by both parties with a deadline of 12th June, according to a Financial Times ...

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers rega ...

This article summarizes recent developments in the health sector, including major acquisitions, drug trial results, and ...